RTTR - Ritter Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Ritter Pharmaceuticals, Inc.

1880 Century Park East
Suite 1000
Los Angeles, CA 90067
United States

Full Time Employees7

Key Executives

Mr. Ira E. RitterCo-Founder, Exec. Chairman & Chief Strategic Officer405.9kN/A69
Mr. Michael D. StepCEO & Director376.27kN/A58
Mr. Andrew J. RitterCo-Founder, Pres, Corp. Sec. & Director441.19kN/A35
Mr. Jeffrey BenjaminPrincipal Financial Officer & Principal Accounting OfficerN/AN/A53
Ms. Ellen F. MochizukiConsultantN/AN/A51
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Ritter Pharmaceuticals, Inc., a specialty pharmaceutical company, develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b/3 clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. It is also exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treating/preventing various conditions, including gastrointestinal diseases, immuno-oncology, metabolic, and liver disease. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.

Corporate Governance

Ritter Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.